Ghent University Academic Bibliography

Your filters: cql: author="Machiels, Jean-Pascal" or (type any "bookEditor issueEditor" and editor="Machiels, Jean-P...

Add to list
- Journal Article
- A1
- open access
Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinib

Ahmad Awada, Thierry Berghmans, Paul M. Clement, Kristof Cuppens, Bram De Wilde (UGent) , Jean-Pascal Machiels, Patrick Pauwels, Marc Peeters, Sylvie Rottey (UGent) and Eric Van Cutsem

(2022) CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 169.
Add to list
- Journal Article
- A1
- open access
Phase I/IIa trial of BMS-986148, an anti-mesothelin antibody–drug conjugate, alone or in combination with nivolumab in patients with advanced solid tumors

Sylvie Rottey (UGent) , Jeffrey Clarke, Kyaw Aung, Jean-Pascal Machiels, Ben Markman, Kimberley M. Heinhuis, Michael Millward, Martijn Lolkema, Sandip Pravin Patel, Paul de Souza, et al.

(2022) CLINICAL CANCER RESEARCH. 28(1). p.95-105
Add to list
A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck : the I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial

Rachel Galot, Christophe Le Tourneau, Esma Saada-Bouzid, Amaury Daste, Caroline Even, Philip Debruyne, Stéphanie Henry, Sylvie Zanetta, Anemie Rutten, Lisa Licitra, et al.

(2021) EUROPEAN JOURNAL OF CANCER. 158. p.17-26
Add to list
Phase 1 study of AMG 160, a half-life extended BITE (R) (bispecific T-cell engager) therapy targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer

Tanya Dorff, Matthew Rettig, Jean-Pascal Machiels, Martijn Lolkema, Karen Autio, Richard Greil, Sylvie Rottey (UGent) , Nabil Adra, Mark Salvati, Shirley Poon, et al.

(2020) JOURNAL FOR IMMUNOTHERAPY OF CANCER. 8(Supplement: 3). p.A207-A208
Add to list
- Journal Article
- A1
- open access
On-target pharmacodynamic activity of the PI3K inhibitor copanlisib in paired biopsies from patients with malignant lymphoma and advanced solid tumors

Franck Morschhauser, Jean-Pascal Machiels, Gilles Salles, Sylvie Rottey (UGent) , Simon A. J. Rule, David Cunningham, Frederic Peyrade, Christophe Fruchart, Hendrik-Tobias Arkenau, Isabelle Genvresse, et al.

(2020) MOLECULAR CANCER THERAPEUTICS. 19(2). p.468-478
Add to list
- Journal Article
- A1
- open access
Oncological care organisation during COVID-19 outbreak

Concetta Elisa Onesti, Hope S. Rugo, Daniele Generali, Marc Peeters, Khalil Zaman, Hans Wildiers, Nadia Harbeck, Miguel Martin, Massimo Cristofanilli, Javier Cortes, et al.

(2020) ESMO OPEN. 5(4).
Add to list
- Journal Article
- A1
- open access
Phase 1 study evaluating the association of the cyclin-dependent kinase 4/6 inhibitor ribociclib and cetuximab in recurrent/metastatic p16-negative squamous cell carcinoma of the head and neck

Emmanuel Seront, Sandra Schmitz, Matthias Papier, Aline van Maanen, Stéphanie Henry, Christophe Lonchay, Sylvie Rottey (UGent) , Gabrielle van Caloen and Jean-Pascal Machiels

(2019) FRONTIERS IN ONCOLOGY. 9.
Add to list
- Journal Article
- A1
- open access
A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)

Jean-Pascal Machiels, Ramon Salazar, Sylvie Rottey (UGent) , Ignacio Duran, Luc Dirix, Karen Geboes (UGent) , Christine Wilkinson-Blanc, Gillian Pover, Simon Alvis, Brian Champion, et al.

(2019) JOURNAL FOR IMMUNOTHERAPY OF CANCER. 7.
Add to list
Which factors predict overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate post-docetaxel?

Charles Van Praet (UGent) , Sylvie Rottey (UGent) , Fransien Van Hende, Gino Pelgrims, Wim Demey, Filip Van Aelst, Wim Wynendaele, Thierry Gil, Peter Schatteman, Bertrand Filleul, et al.

(2017) CLINICAL GENITOURINARY CANCER. 15(4). p.502-508
Add to list
- Journal Article
- A1
- open access
A phase I pharmacokinetic and safety study of cabazitaxel in adult cancer patients with normal and impaired renal function

Analía Azaro, Jordi Rodón, Jean-Pascal Machiels, Sylvie Rottey (UGent) , Silvia Damian, Richard Baird, Javier Garcia-Corbacho, Ron HJ Mathijssen, Pierre-François Clot, Claudine Wack, et al.

(2016) CANCER CHEMOTHERAPY AND PHARMACOLOGY. 78(6). p.1185-1197

Academic Bibliography

Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinib

Phase I/IIa trial of BMS-986148, an anti-mesothelin antibody–drug conjugate, alone or in combination with nivolumab in patients with advanced solid tumors

A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck : the I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial

Phase 1 study of AMG 160, a half-life extended BITE (R) (bispecific T-cell engager) therapy targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer

On-target pharmacodynamic activity of the PI3K inhibitor copanlisib in paired biopsies from patients with malignant lymphoma and advanced solid tumors

Oncological care organisation during COVID-19 outbreak

Phase 1 study evaluating the association of the cyclin-dependent kinase 4/6 inhibitor ribociclib and cetuximab in recurrent/metastatic p16-negative squamous cell carcinoma of the head and neck

A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)

Which factors predict overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate post-docetaxel?

A phase I pharmacokinetic and safety study of cabazitaxel in adult cancer patients with normal and impaired renal function

Contents

Support

Contact